EXAS:NSC-Exact Sciences Corporation (USD)

EQUITY | Diagnostics & Research | NASDAQ Capital Market

Last Closing

USD 43.66

Change

0.00 (0.00)%

Market Cap

USD 1.60B

Volume

1.34M

Analyst Target

USD 116.50
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Exact Sciences Corp is a molecular diagnostics company currently focused on the early detection and prevention of colorectal cancer. It has developed a non?invasive, patient friendly screening test called Cologuard(R).

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-30 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

N/A

USD 33.82B
NTRA Natera Inc

N/A

USD 21.03B
ICLR ICON PLC

N/A

USD 14.94B
ILMN Illumina Inc

N/A

USD 14.06B
MEDP Medpace Holdings Inc

N/A

USD 9.97B
GH Guardant Health Inc

N/A

USD 4.85B
RDNT RadNet Inc

N/A

USD 3.68B
SHC Sotera Health Co

N/A

USD 3.23B
WGS GeneDx Holdings Corp.

N/A

USD 2.75B
VCYT Veracyte Inc

N/A

USD 2.48B

ETFs Containing EXAS

LABS 0.00 % 0.45 %

N/A

N/A
BTEC 0.00 % 0.42 %

N/A

N/A
TWOK 0.00 % 0.10 %

N/A

N/A
XBI SPDR® S&P Biotech ETF 0.00 % 0.35 %

N/A

N/A
NIFE 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange (NASDAQ Capital Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -22.30% 49% F 29% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -22.30% 49% F 29% F
Trailing 12 Months  
Capital Gain -36.78% 49% F 29% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -36.78% 49% F 29% F
Trailing 5 Years  
Capital Gain -24.72% 55% F 29% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -24.72% 55% F 28% F
Average Annual (5 Year Horizon)  
Capital Gain -1.84% 52% F 34% F
Dividend Return -1.84% 52% F 31% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 52.03% 56% F 36% F
Risk Adjusted Return -3.54% 52% F 33% F
Market Capitalization 1.60B 88% B+ 92% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Diagnostics & Research) Ratio vs. Market (NASDAQ Capital Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 3.42 39% 33%
Price / Cash Flow Ratio 40.25 10% 7%
Price/Free Cash Flow Ratio 215.11 3% 2%
Management Effectiveness  
Return on Equity -37.09% 48% 37%
Return on Invested Capital -20.15% 59% 34%
Return on Assets -1.87% 80% 48%
Debt to Equity Ratio 96.62% 27% 23%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector